We are live on ! Find out more
WIM

Woodford Investment Management Portfolio holdings

AUM $310M
1-Year Est. Return 17.41%
This Fund
S&P 500
This Quarter Est. Return
+8.1%
1 Year Est. Return
-17.41%
3 Year Est. Return
-27.14%
5 Year Est. Return
+68.29%
10 Year Est. Return
–
AUM
$2.42B
AUM Growth
+$338M
Cap. Flow
+$164M
Cap. Flow %
6.81%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
5
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$68.5M
2
PRTA icon
Prothena Corp
PRTA
+$41.8M
3
BIVV
Bioverativ Inc. Common Stock
BIVV
+$39M
4
BIIB icon
Biogen
BIIB
+$36.3M
5
TBPH icon
Theravance Biopharma
TBPH
+$6.31M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$19.8M
2
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$8.64M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$431B
$711M 29.45%
10,917,258
-315,500
-3% -$19.8M
PRTA icon
2
Prothena Corp
PRTA
$449M
$619M 25.64%
11,106,211
+795,700
+8% +$41.8M
ALKS icon
3
Alkermes
ALKS
$8.11B
$437M 18.09%
7,470,528
+19,400
+0.3% +$1.1M
TBPH icon
4
Theravance Biopharma
TBPH
$877M
$394M 16.31%
10,705,108
+197,500
+2% +$6.31M
GILD icon
5
Gilead Sciences
GILD
$162B
$108M 4.47%
1,588,100
+973,800
+159% +$68.5M
BIIB icon
6
Biogen
BIIB
$30.5B
$103M 4.26%
376,788
+128,258
+52% +$36.3M
BIVV
7
DELISTED
Bioverativ Inc. Common Stock
BIVV
$43.1M 1.78%
+791,264
New +$39M
NWBO
8
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
– –
-24,815,028
Closed -$8.64M

Similar funds

LCM
Lucha Capital Management San Francisco, California $327M AUM 2.87% 1-Year Est. Return
GWA
Guidant Wealth Advisors Palatine, Illinois $269M AUM 2.79% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
AEPG
American Economic Planning Group Warren, New Jersey $367M AUM 2.51% 1-Year Est. Return
AR
Argyll Research Wilmington, Delaware $377M AUM 4.86% 1-Year Est. Return
KCM
Keywise Capital Management Grand Cayman, Cayman Islands $220M AUM 21.27% 1-Year Est. Return
COI
Capital One Investing Mclean, Virginia $430M AUM 3.49% 1-Year Est. Return

Woodford Investment Management's Q1 2017 Portfolio in Review

As of Q1 2017, Woodford Investment Management held 8 positions worth $2.42B, up 16% from $2.08B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Woodford Investment Management deployed $164M of net new capital in Q1 2017, opening 1 new position and adding to 5 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 791,264 shares worth $43.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was AbbVie, an estimated $19.8M trimmed.

  • Woodford Investment Management's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 791,264 shares worth $43.1M.
  • Woodford Investment Management added most to Gilead Sciences in Q1 2017, an estimated $68.5M increase.
  • Woodford Investment Management's biggest Q1 2017 reduction was AbbVie, cutting an estimated $19.8M.
  • Woodford Investment Management fully exited Northwest Biotherapeutics, Inc. Common stock in Q1 2017, selling an estimated $8.64M.
  • Woodford Investment Management's ten largest holdings make up 100% of its $2.42B portfolio in Q1 2017.
  • Woodford Investment Management opened 1 new position and closed 1 in Q1 2017.
  • Woodford Investment Management's portfolio value rose 16% quarter-over-quarter to $2.42B.

Based on Woodford Investment Management's 13F filing for Q1 2017, filed 12 May 2017.